Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus toripalimab in advanced penile cancer after cisplatin-based chemotherapy
ChiCTR2400086605Phase 2Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and toripalimab in penile squamous cell carcinoma (PSCC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Objective response rate. Started Jul 2024; status: recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on ChiCTR2400086605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086605.